Depression as Measured by the Beck Depression Inventory-II among Injecting Drug Users

Saved in:
Bibliographic Details
Title: Depression as Measured by the Beck Depression Inventory-II among Injecting Drug Users
Language: English
Authors: Johnson, Mark E., Neal, David B., Brems, Christiane, Fisher, Dennis G.
Source: Assessment. 2006 13(2):168-177.
Availability: SAGE Publications. 2455 Teller Road, Thousand Oaks, CA 91320. Tel: 800-818-7243; Tel: 805-499-9774; Fax: 800-583-2665; Web site: http://sagepub.com.
Peer Reviewed: Y
Page Count: 10
Publication Date: 2006
Document Type: Journal Articles
Reports - Research
Descriptors: Depression (Psychology), Factor Analysis, Symptoms (Individual Disorders), Psychiatry, Substance Abuse, Correlation, Psychometrics, Models, Psychological Evaluation
Assessment and Survey Identifiers: Beck Depression Inventory
DOI: 10.1177/1073191106286951
ISSN: 1073-1911
Abstract: This study conducts a confirmatory factor analysis of the Beck Depression Inventory-II (BDI-II) with a sample of 598 individuals who reported recent injecting drug use. Findings indicate that out of four models tested, the best model for this sample is a three-factor solution (somatic, affective, and cognitive) previously reported by Buckley, Parker, and Heggie. The findings that nearly 50% of participants provided BDI-II scores indicating significant depressive symptomatology reveals that these individuals are in need of treatment for their psychiatric symptoms as well as substance use. Somatic symptoms are endorsed more strongly than affective or cognitive symptoms of depression, suggesting a possible, but yet poorly defined, relationship between depressive symptomatology and drug use that centers on shared somatic symptomatology. (Contains 4 tables and 1 figure.)
Abstractor: Author
Number of References: 47
Entry Date: 2006
Accession Number: EJ736640
Database: ERIC
Description
Abstract:This study conducts a confirmatory factor analysis of the Beck Depression Inventory-II (BDI-II) with a sample of 598 individuals who reported recent injecting drug use. Findings indicate that out of four models tested, the best model for this sample is a three-factor solution (somatic, affective, and cognitive) previously reported by Buckley, Parker, and Heggie. The findings that nearly 50% of participants provided BDI-II scores indicating significant depressive symptomatology reveals that these individuals are in need of treatment for their psychiatric symptoms as well as substance use. Somatic symptoms are endorsed more strongly than affective or cognitive symptoms of depression, suggesting a possible, but yet poorly defined, relationship between depressive symptomatology and drug use that centers on shared somatic symptomatology. (Contains 4 tables and 1 figure.)
ISSN:1073-1911
DOI:10.1177/1073191106286951